La FDA aprueba los refuerzos bivalentes contra la COVID para los niños de a partir de 6 meses
JUEVES, 8 de diciembre de 2022 (HealthDay News) — Los refuerzos bivalentes actualizados contra la COVID-19 cuentan ahora con la aprobación para su uso en niños de incluso apenas 6 meses, anunció hoy la Administración de Alimentos y Medicamentos (FDA)…
Learn MoreViral Rebound Uncommon After Molnupiravir, Nirmatrelvir-Ritonavir Therapy
FRIDAY, Dec. 9, 2022 (HealthDay News) — Patients with COVID-19 taking molnupiravir or nirmatrelvir-ritonavir rarely have viral rebound, and rebound is not associated with increased mortality risk, according to a study published online Dec. 6 in JAMA …
Learn MorePaxlovid Safe for Pregnant Patients With COVID-19
FRIDAY, Dec. 9, 2022 (HealthDay News) — Pregnant patients treated with nirmatrelvir and ritonavir (Paxlovid) for COVID-19 tolerate the treatment well, according to a study published online Nov. 29 in JAMA Network Open.William M. Garneau, M.D., from t…
Learn MoreFDA Approves Bivalent COVID-19 Boosters for Children 6 Months and Older
THURSDAY, Dec. 8, 2022 (HealthDay News) — The updated bivalent COVID-19 boosters are now approved for use in children as young as 6 months of age, the U.S. Food and Drug Administration announced today.Children can receive either a Moderna or Pfizer-B…
Learn MorePaxlovid pronto no será gratuito para los estadounidenses
MIÉRCOLES, 7 de diciembre de 2022 (HealthDay News) — El antiviral Paxlovid ha evitado que las personas enfermen de gravedad y mueran por la COVID-19 desde que salió, sin ningún costo para ellas.Pero a mediados del próximo año, el gobierno de EE. UU. …
Learn MoreFDA OKs Bivalent COVID Boosters for Kids 6 Months and Older
THURSDAY, Dec. 8, 2022 (HealthDay News) — The updated bivalent COVID-19 boosters are now approved for use in children as young as 6 months of age, the U.S. Food and Drug Administration announced today.Children can receive either a Moderna or Pfizer-B…
Learn MoreCOVID-19 Vaccine Prevents Against Reinfection
WEDNESDAY, Dec. 7, 2022 (HealthDay News) — Completing a primary COVID-19 vaccination series is associated with significant protection against reinfection among previously infected individuals, according to a study published online Nov. 22 in PLOS Med…
Learn MorePaxlovid Soon Will Not Be Free for Americans
WEDNESDAY, Dec. 7, 2022 (HealthDay News) — The antiviral Paxlovid has kept patients from becoming severely ill and dying from COVID-19 since it became available — at no cost to them. But by the middle of next year, the U.S. government will stop subs…
Learn MorePaxlovid Soon Won’t Be Free for Americans
WEDNESDAY, Dec. 7, 2022 (HealthDay News) — The antiviral Paxlovid has kept people from getting really sick and dying from COVID-19 since it became available — at no cost to them. But by the middle of next year, the U.S. government will stop subsidiz…
Learn MoreSGLT-2i Use Before COVID-19 May Reduce Adverse Outcomes in Diabetes Patients
WEDNESDAY, Dec. 7, 2022 (HealthDay News) — For patients with diabetes subsequently diagnosed and hospitalized with COVID-19, use of a sodium-glucose cotransporter-2 inhibitor (SGLT-2i) before COVID-19 infection is associated with lower COVID-19-relat…
Learn More